Clovis Oncology Aktie [WKN DE: A1JPJY / ISIN: US1894641000]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Clovis Oncology Inc.

26.02.19		Clovis Oncology Announces 2018 Operating Results (Businesswire)
22.02.19		Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference (Businesswire)
12.02.19		Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26 (Businesswire)
24.01.19		Clovis Oncology Announces European Commission Authorization of Rubraca®? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer (Businesswire)
07.01.19		Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018 (Businesswire)
02.01.19		Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference (Businesswire)
14.12.18		CHMP gibt positive Stellungnahme für die neue Indikation der Rubraca®-Tabletten von Clovis Oncology ? (Rucaparib) als Erhaltungstherapie für Frauen mit rückläufigem Eierstockkrebs ab (Businesswire)
04.12.18		Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca® (Businesswire)
20.11.18		Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035 (Businesswire)
07.11.18		Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference (Businesswire)
01.11.18		FDA Approves 3rd Humira Biosimilar, CLVS Tanks On Q3 Results, CRY On Watch (RTTNews)
30.10.18		Clovis Oncology Announces Third Quarter 2018 Operating Results (Businesswire)
23.10.18		ADAP Down 46% This Month, CLVS Abuzz, ADRO Awaits Data In Nov. (RTTNews)
16.10.18		Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30 (Businesswire)
11.10.18		Clovis Oncology Appoints Two New Directors to its Board (Businesswire)
03.10.18		Clovis Oncology to Highlight Results from Rubraca® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress (Businesswire)
02.10.18		Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC) (Businesswire)
19.09.18		Clovis Oncology, Executives Charged With Misleading Investors About Cancer Drug (RTTNews)
06.09.18		Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference (Businesswire)
08.08.18		Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial (Businesswire)
01.08.18		Clovis Oncology Announces Second Quarter 2018 Operating Results (Businesswire)
18.07.18		Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1 (Businesswire)
06.07.18		BIIB One Step Closer, MBVX To Be Delisted, RGLS In The Red On Pink Slip Woes (RTTNews)
05.07.18		Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca®? (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer (Businesswire)
11.06.18		Clovis Oncology to Present at the Goldman Sachs 39th Annual Global Healthcare Conference 2018 (Businesswire)
04.06.18		Clovis Oncology Submits Application to EMA to Expand Use of Rubraca®? (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer (Businesswire)
30.05.18		AKER Withdraws 510(K), TTOO Turns Head, CPRX, LOXO To Face FDA In Nov. (RTTNews)
16.05.18		Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting (Businesswire)
09.05.18		Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018 (Businesswire)
08.05.18		Clovis Oncology Announces First Quarter 2018 Operating Results (Businesswire)
24.04.18		Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8 (Businesswire)
17.04.18		Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock (Businesswire)
16.04.18		Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Businesswire)
06.04.18		Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer (Businesswire)
01.04.18		An Ear To The Pharma: 5 Stocks To Watch This Week (RTTNews)
28.03.18		Biotech Stocks Facing FDA Decision In April (RTTNews)
26.03.18		CHMP Says Yes To CLVS, No To PTLA, NVCN Put On Notice, OGEN To Report Data In Q2 (RTTNews)
23.03.18		Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe (Businesswire)
23.03.18		CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets (Businesswire)
08.03.18		Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035 (Businesswire)
07.03.18		Clovis Oncology to Present at the Barclays Global Healthcare Conference (Businesswire)
22.02.18		ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails (RTTNews)
12.02.18		Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26 (Businesswire)
04.01.18		Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
19.12.17		Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018 (Businesswire)
06.12.17		NVO Gets FDA Nod, GALT Down But Not Out, BIOC Gets A Boost, CUR Excited (RTTNews)
05.12.17		Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application (Businesswire)
09.11.17		Clovis Oncology to Present at the Stifel 2017 Healthcare Conference (Businesswire)
01.11.17		Clovis Oncology Announces Third Quarter 2017 Operating Results (Businesswire)
10.10.17		CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch (RTTNews)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Mit Ripple zum Millionär aufsteigen? So könnte es klappen!

Diese Aktien empfehlen Experten zu kaufen

Bitcoinkurs übersteigt 100.000-Dollar-Schwelle und gibt dann Gewinn wieder komplett ab

Krypto top, Gold flop: Aus diesen Gründen setzt Mark Cuban bei Wirtschaftsschwäche auf Bitcoin

Goldpreis: Ruhe vor dem nächsten Sturm?

DAX Rises Nearly 1% On Encouraging Earnings, Economic Data

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	10.02.2025 11:34
Kaufwert:	EUR
	Hinzufügen Speichern